Overview

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Status:
Recruiting

Trial end date:
2023-08-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors (ICIs) treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Hunan Cancer Hospital

Collaborator:

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Treatments:

Apatinib